Radiotherapy & Oncology
Volume 88, Issue 3 , Pages 335-341 , September 2008

Additional PET/CT in week 5–6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?

  • Charles Gillham

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • ,
  • Daniel Zips

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Department of Radiation Oncology, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • Corresponding Author InformationCorresponding author. Daniel Zips, Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
    • ,
  • Falk Pönisch

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • ,
  • Carsten Evers

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Department of Radiation Oncology, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • ,
  • Wolfgang Enghardt

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • ,
  • Nasreddin Abolmaali

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • ,
  • Klaus Zöphel

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Department of Nuclear Medicine, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • ,
  • Steffen Appold

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Department of Radiation Oncology, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • ,
  • Tobias Hölscher

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Department of Radiation Oncology, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • ,
  • Jörg Steinbach

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • PET Centre, Research Centre Dresden-Rossendorf, Germany
    • Institute of Radiopharmacy, Research Centre Dresden-Rossendorf, Germany
    • ,
  • Jörg Kotzerke

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Department of Nuclear Medicine, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • PET Centre, Research Centre Dresden-Rossendorf, Germany
    • ,
  • Thomas Herrmann

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Department of Radiation Oncology, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
    • ,
  • Michael Baumann

      Affiliations

    • OncoRay, Centre for Radiation Research in Oncology, Technische Universität Dresden, Germany
    • Department of Radiation Oncology, Technische Universität Dresden, Germany
    • Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany

Received 15 December 2007 ,Revised 4 April 2008 ,Accepted 1 May 2008.

References 

  1. Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999;52:137–148
  2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899–909.
  3. Baumann M, Appold S, Petersen C, Zips D, Herrmann T. Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer. Lung Cancer. 2001;33(Suppl 1):S35–S45
  4. Baumann M, Krause M, Zips D, et al. Molecular targeting in radiotherapy of lung cancer. Lung Cancer. 2004;45(Suppl 2):S187–S197
  5. Rengan R, Rosenzweig KE, Venkatraman E, et al. Improved local control with higher doses of radiation in large-volume stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;60:741–747
  6. Willner J, Baier K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and tumor control prediction in primary radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:382–389
  7. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol. 2001;19:127–136
  8. Narayan S, Henning GT, Ten Haken RK, et al. Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer. Lung Cancer. 2004;44:79–88
  9. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004;22:4341–4350
  10. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2002;54:348–356
  11. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:318–328
  12. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324–333
  13. Belderbos JS, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a Phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126–134
  14. Thirion P, Holmberg O, Collins CD, et al. Escalated dose for non-small cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol. 2004;71:163–166
  15. De Ruysscher D, Wanders R, van Haren E, et al. HI-CHART: a Phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;
  16. Miller KL, Shafman TD, Anscher MS, et al. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?. Int J Radiat Oncol Biol Phys. 2005;61:64–69
  17. De Ruysscher D, Wanders S, van Haren E, et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2005;62:988–994
  18. Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non-small cell lung cancer. J Clin Oncol. 2007;
  19. De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose-limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol. 2005;77:5–10
  20. Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol. 2006;81:209–225
  21. Lavrenkov K, Partridge M, Cook G, Brada M. Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. Radiother Oncol. 2005;77:1–4
  22. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317–324
  23. van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys. 2007;68:771–778
  24. Yom SS, Liao Z, Liu HH, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:94–102
  25. Lavrenkov K, Christian JA, Partridge M, et al. A potential to reduce pulmonary toxicity: the use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer. Radiother Oncol. 2007;83:156–162
  26. Guckenberger M, Meyer J, Wilbert J, et al. Intra-fractional uncertainties in cone-beam CT-based image-guided radiotherapy (IGRT) of pulmonary tumors. Radiother Oncol. 2007;83:57–64
  27. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1087–1096
  28. McDermott LN, Wendling M, Sonke JJ, van Herk M, Mijnheer BJ. Anatomy changes in radiotherapy detected using portal imaging. Radiother Oncol. 2006;79:211–217
  29. Bosmans G, van Baardwijk A, Dekker A, et al. Time trends in nodal volumes and motion during radiotherapy for patients with stage III Non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2008;71:139–144
  30. Britton KR, Starkschall G, Tucker SL, et al. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys. 2007;68:1036–1046
  31. Bosmans G, van Baardwijk A, Dekker A, et al. Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2006;66:748–753
  32. Kupelian PA, Ramsey C, Meeks SL, et al. Serial megavoltage CT imaging during external beam radiotherapy for non-small cell lung cancer: observations on tumor regression during treatment. Int J Radiat Oncol Biol Phys. 2005;63:1024–1028
  33. Erridge SC, Seppenwoolde Y, Muller SH, et al. Portal imaging to assess set-up errors, tumor motion and tumor shrinkage during conformal radiotherapy of non-small cell lung cancer. Radiother Oncol. 2003;66:75–85
  34. Siker ML, Tome WA, Mehta MP. Tumor volume changes on serial imaging with megavoltage CT for non-small cell lung cancer during intensity-modulated radiotherapy: how reliable, consistent, and meaningful is the effect?. Int J Radiat Oncol Biol Phys. 2006;66:135–141
  35. Underberg RW, Lagerwaard FJ, van Tinteren H, et al. Time trends in target volumes for stage I non-small cell lung cancer after stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:1221–1228
  36. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer. 1999;24:31–37
  37. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys. 2003;55:724–735
  38. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1–9
  39. Senan S, De Ruysscher D, Giraud P, Mirimanoff R, Budach V. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol. 2004;71:139–146
  40. Kim TH, Cho KH, Pyo HR, et al. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:995–1002
  41. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  42. Grosu AL, Piert M, Weber WA, et al. Positron emission tomography for radiation treatment planning. Strahlenther Onkol. 2005;181:483–499
  43. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001;51:923–931
  44. Fox JL, Rengan R, O’Meara W, et al. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small cell lung cancer?. Int J Radiat Oncol Biol Phys. 2005;62:70–75
  45. Steenbakkers RJ, Duppen JC, Fitton I, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. Int J Radiat Oncol Biol Phys. 2006;64:435–448
  46. van Baardwijk A, Bosmans G, Dekker A, et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol. 2007;82:145–152
  47. Eschmann SM, Friedel G, Paulsen F, et al. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2007;55:165–171
  48. Madani I, Duthoy W, Derie C, et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68:126–135
  49. Schütze C, Bergmann R, Yaromina A, et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG-uptake in FaDu tumours in nude mice. Radiother Oncol. 2007;83:311–315

PII: S0167-8140(08)00243-0

doi: 10.1016/j.radonc.2008.05.004

Radiotherapy & Oncology
Volume 88, Issue 3 , Pages 335-341 , September 2008

Article Tools

* Image Usage & Resolution